Mohammad Ali Sheffeh, MD, from the Mayo Clinic in Rochester, Minnesota, and colleagues examined the efficacy of GLP-1 RA or SGLT-2i initiation for reducing mortality or cardiovascular events among ...

(HealthDay News) — There is a small inverse association between plasma omega-6 and omega-3 polyunsaturated fatty acids (PUFAs) and cancer, according to a study published online in the International ...

Preclinical studies have shown AT-02 is able to bind to multiple amyloid types and can induce macrophage mediated amyloid phagocytosis and removal. The Food and Drug Administration has granted Orphan ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

Supply chain issues are more likely to result in drug shortages in the United States than in Canada, data suggest.

SGLT2 inhibitors and GLP-1 receptor agonists exhibit renoprotective effects in patients with CKD with and without diabetes.

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

Drugs for diabetic kidney disease treatment have greatly expanded, allowing research and consensus on their optimal use.

(HealthDay News) — Elevated baseline resting heart rate (RHR) is associated with an increased risk for incident atrial fibrillation (AF) in Black adults, according to a study published online in JAMA ...

A multi-pronged intervention reduced prior authorization delays and denials for patients treated in a radiation oncology department.

Clinicians treating patients with kidney disease must be aware of dental considerations to avoid potentially lethal consequences.

35% lower risk for diabetes, 20% reduced risk for hypertension seen for sugar restriction in first 3 years after conception ...